Semanteon Capital Management LP Purchases New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Semanteon Capital Management LP purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,120 shares of the biotechnology company’s stock, valued at approximately $1,265,000. Sarepta Therapeutics comprises about 0.9% of Semanteon Capital Management LP’s investment portfolio, making the stock its 10th biggest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. DMC Group LLC raised its position in Sarepta Therapeutics by 2.9% in the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 93 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares during the last quarter. Natixis Advisors L.P. raised its position in Sarepta Therapeutics by 0.6% during the 3rd quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company’s stock worth $3,155,000 after buying an additional 160 shares during the last quarter. LGL Partners LLC raised its position in Sarepta Therapeutics by 4.6% during the 3rd quarter. LGL Partners LLC now owns 4,196 shares of the biotechnology company’s stock worth $509,000 after buying an additional 186 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its position in Sarepta Therapeutics by 6.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 3,244 shares of the biotechnology company’s stock worth $393,000 after buying an additional 196 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on SRPT shares. Wedbush restated an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Citigroup upped their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $128.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Finally, BMO Capital Markets started coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target for the company. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the sale, the director now directly owns 6,621 shares of the company’s stock, valued at approximately $814,118.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Stephen Mayo sold 3,135 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total transaction of $385,479.60. Following the transaction, the director now owns 6,621 shares in the company, valued at $814,118.16. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock valued at $2,739,419 in the last ninety days. Insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded up $3.14 during trading hours on Thursday, reaching $127.39. The company’s stock had a trading volume of 1,694,283 shares, compared to its average volume of 994,316. The stock has a market cap of $11.96 billion, a PE ratio of -20.82 and a beta of 0.94. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company’s 50-day moving average is $126.22 and its two-hundred day moving average is $110.43. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The firm had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm’s revenue was up 53.6% on a year-over-year basis. During the same period in the prior year, the company earned ($1.24) EPS. Analysts forecast that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.